Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049692 | 0.77 | MAOA (0.31) | MAOAMAOB | |
| SCHEMBL14697151 | 0.77 | MAOA (0.31) | MAOAMAOB | |
| SCHEMBL29404792 | 0.77 | HTR2A (0.38) | MAOAMAOBHTR2ACYP2D6MEN1 | |
| SCHEMBL15049597 | 0.77 | MAOA (0.31) | MAOAMAOB | |
| SCHEMBL1974788 | 0.77 | HTR2A (0.38) | MAOAMAOBHTR2ACYP2D6MEN1 | |
| SCHEMBL4436919 | 0.71 | CYP19A1 (0.38) | HTR2A | |
| SCHEMBL7467393 | 0.71 | HTR2A (0.38) | HTR2AMEN1KMT2A | |
| SCHEMBL15049695 | 0.71 | HTR2A (0.32) | HTR2A | |
| SCHEMBL6722814 | 0.69 | ATM (0.39) | GAAKMT2A | |
| SCHEMBL4430948 | 0.68 | MEN1 (0.40) | CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716381-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114634447-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114621146-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114605327-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114591242-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114573510-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-108473481-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-113636978-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113603645-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| WO-2013033310-A1 | MODULATORS OF REV-ERB | KAMENECKA THEODORE MARK (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-7910751-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | MOCHIDA PHARMACEUTICAL CO.,LTD (JP) | 2008-11-20 | — | — | US | disclosed |
| CN-101228131-A | Novel heterocyclylideneacetamide derivatives | MOCHIDA PHARM CO LTD (JP) | 2008-07-23 | — | — | CN | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-0650476-B1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMA CO LTD (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6136826-A | AMINOPIPERIDINE COMPOUNDS SUBSTITUTED WITH ALKANOYL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| CN-1052224-C | Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients | OTSUKA PHARMA CO LTD (JP) | 2000-05-10 | — | — | CN | disclosed |
| US-5760058-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5656642-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287428-A1 | Novel Heterocyclidene Acetamide Derivative | TRPV1, TRPV3, TRPA1 | MAOA 1788/4885MAOB 1685/4885HTR2A 388/4885 |
| US-20110112071-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | TRPV1, TRPV3, TRPA1 | MAOA 1788/4885MAOB 1685/4885HTR2A 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.